ES2128309T3 - Utilizacion de taurina para la fabricacion de un medicamento para estimular actividad de mieloperoxidasa. - Google Patents

Utilizacion de taurina para la fabricacion de un medicamento para estimular actividad de mieloperoxidasa.

Info

Publication number
ES2128309T3
ES2128309T3 ES91306903T ES91306903T ES2128309T3 ES 2128309 T3 ES2128309 T3 ES 2128309T3 ES 91306903 T ES91306903 T ES 91306903T ES 91306903 T ES91306903 T ES 91306903T ES 2128309 T3 ES2128309 T3 ES 2128309T3
Authority
ES
Spain
Prior art keywords
acid
aminoethanesulphonic
ethanesulphonic
propanesulphonic
taurine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91306903T
Other languages
English (en)
Inventor
Frederick Jacob Bloomfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bloomfield DA
Original Assignee
Bloomfield DA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bloomfield DA filed Critical Bloomfield DA
Application granted granted Critical
Publication of ES2128309T3 publication Critical patent/ES2128309T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

COMPUESTOS DE ION HIBRIDO SELECCIONADOS DE: TAURINA (ACIDO 2-AMINOETANOSULFONICO), 2(N-MORFOLINO) ACIDO ETANOSULFONICO (MES), N-(2 ACETAMINO) ACIDO IMINODIACETICO (ADA), PIPERACINA-N, N'' BIS (ACIDO 2-ETANOSULFONICO (PIPES), ACIDO N-(2-ACETAMIDO)-2-AMINOETANOSULFONICO (ACES), ACIDO N, N-BIS (2-HIDROXIETILO)-2-AMINOETANOSULFONICO (BES), 3-(N-MORFOLINO) PROPANOSULFONICO (MOPS), ACIDO N-N[TRIS (HIDROXIMETILO)-METILO]-2-AMINOETANOSULFONICO (TES), ACIDO N-2-HIDROXIETILPIPERAZINA-N''-2-ETANOSULFONICO (HEPES), ACIDO N-2-HIDROXIETILPIPERAZINA-N''3-PROPANOSULFONICO (H)EPPS), ACIDO 2-(CICLOEXILAMINO) ETANOSULFONICO (CHES) O ACIDO 3-(CICLOEXILAMINO) PROPANOSULFONICO (CAPS), Y SUS DERIVADOS N-HALO PUEDEN USARSE SEPARADAMENTE O EN COMBINACION EN EL TRATAMIENTO DE CONDICIONES CLINICAS RELACIONADAS MEDIANTE LA ESTIMULACION DE ACTIVIDAD MIELOPEROXIDASA, QUE A SU VEZ ESTIMULA LA PRODUCCION DE ACIDO HIPOCLOROSO "IN VIVO", QUE LLEVA "INTER ALIA" A LA INACTIVACION REALZADA LEUKOTRIENA.
ES91306903T 1990-07-30 1991-07-29 Utilizacion de taurina para la fabricacion de un medicamento para estimular actividad de mieloperoxidasa. Expired - Lifetime ES2128309T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE274190 1990-07-30

Publications (1)

Publication Number Publication Date
ES2128309T3 true ES2128309T3 (es) 1999-05-16

Family

ID=11036287

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91306903T Expired - Lifetime ES2128309T3 (es) 1990-07-30 1991-07-29 Utilizacion de taurina para la fabricacion de un medicamento para estimular actividad de mieloperoxidasa.

Country Status (8)

Country Link
US (1) US5248680A (es)
EP (1) EP0469813B1 (es)
JP (1) JPH0597666A (es)
AT (1) ATE175112T1 (es)
AU (1) AU641529B2 (es)
CA (1) CA2048068A1 (es)
DE (1) DE69130692T2 (es)
ES (1) ES2128309T3 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7404967B2 (en) 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
WO1996023490A1 (en) * 1995-02-03 1996-08-08 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5716959A (en) * 1996-02-13 1998-02-10 T. Ronald Theodore Method of treating disease with piperazine zwitterion compounds
SE9601395D0 (sv) * 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 1
US6111085A (en) * 1996-09-13 2000-08-29 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
AU1608499A (en) * 1997-11-28 1999-06-16 Peter M. Pugliese Zwitterionic fatty acid compounds for anti-inflamation
US6448251B1 (en) * 1997-11-28 2002-09-10 Peter T. Pugliese Zwitterionic-fatty acid compounds having anti-inflammatory properties
US6114337A (en) * 1998-11-27 2000-09-05 Pugliese; Peter T. Zwitteronic-fatty acid compounds having anti-inflammatory properties
WO2002013813A1 (en) * 2000-08-11 2002-02-21 The Lawson Health Research Institute Compositions and methods for inhibiting islet dysfunction and autoimmune disorders
EP1239853B1 (de) * 2000-09-14 2006-11-08 Waldemar Gottardi Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
FR2816837A1 (fr) * 2000-11-17 2002-05-24 Oreal Utilisation d'au moins un derive amino sulfonique dans une composition destinee a favoriser la desquamation de la peau
GB0109428D0 (en) * 2001-04-17 2001-06-06 Process & Ind Design Consultan Therapeutic compositions
DE10133197A1 (de) * 2001-07-07 2003-01-23 Beiersdorf Ag Aminosäuren enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
US20060127342A1 (en) * 2004-12-09 2006-06-15 Georgia Levis Taurine-based compositions, therapeutic methods, and assays
CA2676991A1 (en) * 2007-01-31 2008-08-07 Adam Heller Methods and compositions for the treatment of pain
CN109224077A (zh) 2009-09-17 2019-01-18 比斯普科生物科学有限公司 N-2-羟基-乙基-哌嗪-n’-2-乙磺酸在疼痛控制和脱髓鞘损伤逆转中的作用
US20140377814A1 (en) * 2012-02-07 2014-12-25 Industry-Academic Cooperation Foundation, Yonsei University Method For The Fixation Or Conversion Of High-Pressure Carbon Dioxide Using Barophilic Sulfur-Oxidizing Chemolithoautotrophs
JP2014040393A (ja) * 2012-08-23 2014-03-06 Taisho Pharmaceutical Co Ltd 遺伝子発現調節剤
JP6738280B2 (ja) * 2014-10-24 2020-08-12 株式会社 資生堂 角層剥離の抑制又は亢進に起因する肌状態を改善するための美容方法及び評価方法
RU2614691C2 (ru) * 2015-07-14 2017-03-28 Федеральное государственное бюджетное научное учреждение "Институт экспериментальной медицины" (ФГБНУ "ИЭМ") Гепатопротекторное средство

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52977B1 (en) * 1981-11-24 1988-04-27 Pascale Ltd Protective composition for users of cyanoacrylate adhesives
JPS592686A (ja) * 1982-06-25 1984-01-09 Green Cross Corp:The ミエロペルオキシダ−ゼの粉末製剤
CA1206097A (en) * 1982-08-17 1986-06-17 Donncha O'sullivan Pharmaceutical composition
IE853206L (en) * 1985-12-18 1987-06-18 Sullivan Donncha O Use of aminosulfonic acids in treatment of inflammatory¹conditions
GB8713091D0 (en) * 1987-06-04 1987-07-08 Millrine W P Pharmaceutical compositions
EP0361908A3 (en) * 1988-09-28 1990-09-05 Ideon Corporation Combination enzyme immunotherapeutics

Also Published As

Publication number Publication date
DE69130692D1 (de) 1999-02-11
EP0469813A2 (en) 1992-02-05
CA2048068A1 (en) 1992-01-31
DE69130692T2 (de) 1999-09-09
AU8133291A (en) 1992-02-13
EP0469813A3 (en) 1992-11-19
ATE175112T1 (de) 1999-01-15
EP0469813B1 (en) 1998-12-30
US5248680A (en) 1993-09-28
JPH0597666A (ja) 1993-04-20
AU641529B2 (en) 1993-09-23

Similar Documents

Publication Publication Date Title
ES2128309T3 (es) Utilizacion de taurina para la fabricacion de un medicamento para estimular actividad de mieloperoxidasa.
ATE83659T1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
NO890259D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive etylfenoksyacetamider.
FR2692264B1 (fr) Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
DK1056452T3 (da) Indol-3-propionsyre, salte og estere deraf anvendt som medikamenter
HUP9800794A2 (hu) (S)-oxi-butinin és (S)-dezetil-oxi-butinin alkalmazása vizelet inkontinencia kezelésére alkalmazható gyógyszerkészítmények előállítására és a vegyületek előállítása
DE69123960D1 (de) Behandlung von entzündungen
FR2670491B1 (fr) Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant.
ATE224714T1 (de) Behandlung von tinnitus mit neuroprotektiven wirkstoffen
DE4394931T1 (de) Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
DE69127350D1 (de) 6-cyclohexyl-2'-0-methyl-adenosine hydrat und verwendungengen davon
DK324185A (da) 2-substituerede 1,3-propylidendiphosphonatderivater, deres fremstilling og farmaceutiske praeparater med indhold deraf
NO982863L (no) Nye forbindelser med analgetisk effekt
NO971743D0 (no) Farmasöytisk sammensetning for profylakse og behandling av type I allergiske sykdommer
ATE73785T1 (de) 5-(3-alkyl-5-tert.butyl-4-hydroxyphenyl)-2-amin - 6h-1,3,4-thiadiazine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung.
ATE5256T1 (de) Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
ATE1146T1 (de) 3-chlor-6-hydroxy-5-methyl-benzoesaeure-derivate die entsprechenden pharmazeutischen zusammensetzungen, das wachstum bestimmter tiere stimulierende zusammensetzungen und deren herstellung.
ITMI920979A1 (it) N-acil derivati di aminoalcooli come agenti terapeutici attivi sull'edema neurogenico endoneurale a livello del nervo periferico.
CY1107346T1 (el) Φαρμακευτικη συνθεση για την ενδοκυτταρια οξινιση με cis-ουροκανικο οξυ
DE69400352D1 (de) 3- oder 4-Glykosyloxybenzopyranderivat und dieses enthaltende antiallergisches Mittel
IT1223395B (it) Composti ad attivita' cardiovascolare
ATE147396T1 (de) N-substituierte aminomethandiphosphonsäuren
DE69200840D1 (de) Harnstoff- und Thioharnstoffderivate, Herstellung und therapeutische Verwendung.
ATE24834T1 (de) Verwendung von beta-(1-adamantyl)-alpha, alphadimethylethylamin zur herstellung eines arzneimittels zur behandlung von otitis externa bei hunden.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 469813

Country of ref document: ES